EDG-4131 / Edgewise Therap - LARVOL DELTA

Edgewise Therapeutics to Present on Sevasemten for the Treatment of Becker Muscular Dystrophy at the 2025 MDA Clinical and Scientific Conference (Businesswire) - "Edgewise Therapeutics...announced that the company will present data on sevasemten, an investigational orally administered first-in-class fast skeletal myosin inhibitor designed to protect against contraction-induced muscle damage, at the Muscular Dystrophy Association (MDA) Clinical and Scientific Conference. The conference will take place at the Hilton Anatole, Dallas, TX from March 16-19, 2025....A companion poster presentation will be available for Dr. McDonald’s presentation (poster #O78)."

P2 data • Preclinical • Becker Muscular Dystrophy